READDI
  • About Us
    • Leadership
    • Scientific Advisory Board
  • Partners
  • Our Approach
  • Resources
    • Virtual Press Kit
    • News
  • Get Involved
    • Partner with Us
    • Contact Us
  • About Us
    • Leadership
    • Scientific Advisory Board
  • Partners
  • Our Approach
  • Resources
    • Virtual Press Kit
    • News
  • Get Involved
    • Partner with Us
    • Contact Us

News

READDI Receives $65M Grant from NIH to Establish an Antiviral Drug Discovery (AViDD) Center

5/20/2022

 
The READDI-AViDD Center, one of nine established by the NIH, is an integrated public-private partnership with a renowned, interdisciplinary research team of experts from the Gillings School, UNC School of Medicine and UNC Eshelman School of Pharmacy.

Read More

READDI, in Collaboration with Chimerix, to Present at International Conference on Antiviral Research

2/24/2022

 
Preclinical data from the Company’s CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research (ICAR) on Wednesday, March 23, 2022 from 12:15 – 1:00 pm PT. CMX521 was found to significantly reduce lung viral titer and clinical symptoms in a SARS-CoV-2 mouse model.

Read More

READDI Receives $18 Million in State Appropriations

2/11/2022

 
The state funds will allow READDI to build out a small management team, including the initial hire of a CEO, who will work to create broad spectrum antiviral drugs to combat novel coronaviruses, among other viruses.

Read More

READDI awarded $5M by RTI's Forethought Research Collaboration Challenge

11/8/2021

 
READDI was selected from among 136 applications to receive the award, aimed at accelerating the production of antiviral drugs.

Read More

READDI to be featured at UNC's University Research Week

11/4/2021

 
READDI will be featured in "The Health of Our State and Beyond Series" at University of North Carolina's annual University Research Week.

Read More

SAS and Carolina partner to accelerate antiviral drugĀ development

9/14/2021

 
SAS joins Rapidly Emerging Antiviral Drug Development Initiative to advance drug discovery with artificial intelligence and machine learning.

Read More

READDI Advances in RTI Forethought Challenge

8/2/2021

 
READDI is among eight projects selected to advance from 136 proposals initially submitted.

Read More

The race to find covid-19 drug treatments that actually work

6/28/2021

 
We have a bounty of vaccines and more on the way, but drugs that treat the disease are vital too if we want to keep people alive and bring the pandemic under control.

Read More

Why are antivirals so hard to develop?

5/20/2021

 
With few good targets and limited financial incentives, the field of antiviral drug discovery has lagged. The COVID-19 pandemic might be awakening the world to the problem.

Read More

Britain Moves On to the Next Big Covid Problem: Treatment

5/4/2021

 
Boris Johnson wants to do for Covid drugs what he did for vaccines. It’s not that simple.

Read More
<<Previous

    Archives

    May 2022
    February 2022
    November 2021
    September 2021
    August 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    October 2020
    September 2020
    August 2020
    July 2020

    Categories

    All
    Covid

About Us
Leadership
Scientific Advisory Board

Partners
Our Approach
Resources
Virtual Press Kit
News Releases

Get Involved
Partner With Us
Contact Us

Picture
READDI is led by The University of North Carolina at Chapel Hill.
Get Involved
Privacy and Cookies